After Verdict Reversal, Gilead Takes Aim At Merck Patents
Gilead Sciences Inc. reasserted its position Tuesday that two Merck & Co. Inc. patents covering an ingredient in Gilead's hepatitis C drugs are invalid, a month after a California federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article